Pain management最新文献_第10页

Efficacy of transdermal anti-inflammatory patches for musculoskeletal pain: a systematic review and meta-analysis. 透皮消炎贴对肌肉骨骼疼痛的疗效：系统综述和荟萃分析。

IF 1.4

Pain management Pub Date : 2024-10-01 Epub Date: 2024-11-22 DOI: 10.1080/17581869.2024.2421153

María B Sánchez, Michael J Callaghan, James Selfe, Michael Twigg, Toby Smith

{"title":"Efficacy of transdermal anti-inflammatory patches for musculoskeletal pain: a systematic review and meta-analysis.","authors":"María B Sánchez, Michael J Callaghan, James Selfe, Michael Twigg, Toby Smith","doi":"10.1080/17581869.2024.2421153","DOIUrl":"10.1080/17581869.2024.2421153","url":null,"abstract":"Aim: To determine the efficacy of transdermal anti-inflammatory patches in the treatment of acute and chronic musculoskeletal pain.Methods: A comprehensive search of: Cochrane Central register of controlled trials, EMBASE, MEDLINE, CINAHL and PubMed, for studies using transdermal anti-inflammatory patches vs placebo for management of musculoskeletal pain, e.g. soft tissue injuries or tendonitis (last search January 2024). Cochrane Risk of Bias Tools v1 was used for quality assessment and GRADE determined certainty of evidence. Meta-analysis was performed.Results: Twenty-three randomized placebo-controlled trials (n = 4729) were included. There was low-certainty evidence that transdermal patches provided statistically and clinically significant pain relief on movement at long-term follow-up for chronic musculoskeletal pain (effect size -2-69 (95% CI: -4.14, -1.24) and at short-term follow-up which was non-clinically significant, (-1.24: 95% CI: -1.78, -0.69).Conclusion: Several types of transdermal anti-inflammatory patches may offer short-term and long-term pain relief for acute and chronic musculoskeletal conditions. However, the clinical significance of this effect for the long-term pain relief was based on low-certainty evidence of transdermal anti-inflammatory patches versus placebo; for short-term pain there was an overall non-clinically significant improvement. Performing a meta-analysis for all outcomes was not possible due to insufficiency in the evidence-base.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42020185944.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"557-569"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy. 以通俗易懂的语言概述了接受瑞格列奈联合疗法的妇女在子宫肌瘤相关疼痛方面的变化。

IF 1.4

Pain management Pub Date : 2024-09-01 Epub Date: 2024-10-28 DOI: 10.1080/17581869.2024.2408114

Elizabeth A Stewart, Andrea S Lukes, Roberta Venturella, Juan-Camilo Arjona Ferreira, Yulan Li, Elke Hunsche, Rachel B Wagman, Ayman Al-Hendy

{"title":"A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy.","authors":"Elizabeth A Stewart, Andrea S Lukes, Roberta Venturella, Juan-Camilo Arjona Ferreira, Yulan Li, Elke Hunsche, Rachel B Wagman, Ayman Al-Hendy","doi":"10.1080/17581869.2024.2408114","DOIUrl":"10.1080/17581869.2024.2408114","url":null,"abstract":"What is this summary about?: This is a summary of two research studies (known as clinical trials) called LIBERTY 1 and LIBERTY 2. These studies compared how well a medicine called relugolix combination therapy and placebo worked in reducing heavy menstrual bleeding (periods) in women with uterine fibroids (published in a separate article referenced in the section: Where can readers find more information on these studies?). Researchers also looked at whether women with moderate to severe pain from uterine fibroids saw improvement in their worst pain symptoms after 24 weeks of treatment (results described in the present summary).What are the key takeaways?: Women with moderate to severe pain from uterine fibroids (menstrual or nonmenstrual pain) took either relugolix combination therapy or placebo (once daily by mouth) for 24 weeks. During the last 5 weeks of treatment, 65% of women taking relugolix combination therapy and 19% of women taking placebo reported having minimal or no menstrual pain. Similarly, 45% of women taking relugolix combination therapy and 22% of women taking placebo reported having minimal or no non-menstrual pain. During the same time period, 71% of the women taking relugolix combination therapy and 40% of women taking placebo reported their worst pain was reduced by about one third compared with the start of the study.What were the main conclusions reported by the researchers?: Women with moderate to severe pain from uterine fibroids taking relugolix combination therapy were more likely to have minimal or no pain from uterine fibroids after treatment compared with women taking placebo.Clinical Trial Registration: NCT03049735 (LIBERTY 1), NCT03103087 (LIBERTY 2) (ClinicalTrials.gov).","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"469-476"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Galcanezumab add-on in refractory cluster headache. A case series. 加群单抗用于难治性丛集性头痛。病例系列。

IF 1.4

Pain management Pub Date : 2024-09-01 Epub Date: 2024-11-18 DOI: 10.1080/17581869.2024.2427564

Georgios Karagiorgis, Savvas Christofilos, Christina Deligianni, Ioanna Spanou, Sofia Vassilopoulou, Dimos-Dimitrios D Mitsikostas

{"title":"Galcanezumab add-on in refractory cluster headache. A case series.","authors":"Georgios Karagiorgis, Savvas Christofilos, Christina Deligianni, Ioanna Spanou, Sofia Vassilopoulou, Dimos-Dimitrios D Mitsikostas","doi":"10.1080/17581869.2024.2427564","DOIUrl":"10.1080/17581869.2024.2427564","url":null,"abstract":"Cluster headache (CH), a highly disabling condition, lacks disease-specific, mechanism-based prophylactic treatment. Galganezumab, a monoclonal antibody targeting the calcitonin gene-related peptide, reduced the weekly attacks of CH in one randomized, placebo-controlled trial for the prevention of episodic CH (eCH), but this effect was not detected in people with chronic CH (cCH). In this case series, we systematically monitored the efficacy and safety outcomes of adjunctive therapy in 11 people with refractory CH (failure of ≥ 3 prophylactic treatments; eCH n = 5, cCH, n = 6) who received galcanezumab (120-360 mg monthly) for 3 consecutive months. All participants received intermediate treatment with oral steroids or a great occipital nerve block ≥ 2 months before starting galcanezumab treatment. After galcanezumab treatment, the average number of weekly CH attacks and weekly days with any symptomatic treatment for CH decreased significantly from 16.0 ± 9.4 and 6.50 ± 3.59 before treatment to 1.8 ± 1.32 (p = 0.002) and 1.8 ± 3.36 (p = 0.001) at month 3 of treatment, respectively. Two participants with cCH showed no change in the number of attacks with galcanezumab. No serious adverse events were recorded. These data, along with those of previous real-world reports, suggest that galcanezumab may help people with refractory CH as an add-on treatment.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"491-495"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sustained relief with spinal cord stimulator despite anterior lead migration: a case report. 脊髓刺激器在前导联线移位的情况下仍能持续缓解症状：病例报告。

IF 1.4

Pain management Pub Date : 2024-09-01 Epub Date: 2024-10-04 DOI: 10.1080/17581869.2024.2407283

Soun Sheen, Kent Nouri

引用次数: 0

VX-548 in the treatment of acute pain. VX-548 用于治疗急性疼痛。

IF 1.4

Pain management Pub Date : 2024-09-01 Epub Date: 2024-11-18 DOI: 10.1080/17581869.2024.2421749

Aaron Yik Hang Kong, Hon Sen Tan, Ashraf S Habib

{"title":"VX-548 in the treatment of acute pain.","authors":"Aaron Yik Hang Kong, Hon Sen Tan, Ashraf S Habib","doi":"10.1080/17581869.2024.2421749","DOIUrl":"10.1080/17581869.2024.2421749","url":null,"abstract":"Acute pain management requires balancing analgesia with adverse effects risk. The voltage-gated sodium channel NaV1.8 plays an important role in pain physiology, and its inhibition was shown to have analgesic effects. VX-548 is a new oral NaV1.8-specific inhibitor that received United States Food and Drug Administration Fast Track and Breakthrough Therapy designations. Its efficacy was demonstrated in two Phase II trials of patients who underwent abdominoplasty and bunionectomy. These showed that VX-548, when given as an oral loading dose of 100 mg followed by 50 mg 12-hly, significantly decreased pain scores compared with placebo. Similarly, two Phase III trials of patients who underwent abdominoplasty and bunionectomy comparing VX-548 with hydrocodone bitartrate-acetaminophen and placebo reported significantly reduced pain scores compared with placebo, but no improvement compared with hydrocodone bitartrate-acetaminophen. Evidence from Phase II and III trials suggest that VX-548 is well-tolerated, with headache, nausea, constipation and dizziness being the most common adverse effects. However, the safety of prolonged VX-548 administration is uncertain; a Phase II trial of patients with diabetic neuropathy who received high-dose VX-548 over 12 weeks reported decreased creatinine clearance. Data pertaining to VX-548 safety and efficacy within the context of multimodal analgesia and pregnancy are also needed.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"477-486"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combatting opioid misuse, overuse and abuse: a systematic review of pharmacists' services and outcomes. 打击阿片类药物的误用、过量使用和滥用：药剂师服务和成果系统回顾。

IF 1.4

Pain management Pub Date : 2024-09-01 Epub Date: 2024-10-22 DOI: 10.1080/17581869.2024.2411930

Bhuvan Kc, Alian A Alrasheedy, Mohamed Izham Mohamed Ibrahim, Vibhu Paudyal, Christina Malini Christopher, Sunil Shrestha, Shakti Shrestha

{"title":"Combatting opioid misuse, overuse and abuse: a systematic review of pharmacists' services and outcomes.","authors":"Bhuvan Kc, Alian A Alrasheedy, Mohamed Izham Mohamed Ibrahim, Vibhu Paudyal, Christina Malini Christopher, Sunil Shrestha, Shakti Shrestha","doi":"10.1080/17581869.2024.2411930","DOIUrl":"10.1080/17581869.2024.2411930","url":null,"abstract":"Aim: To examine the range of services pharmacists provide and their impact on patient outcomes, harm reduction, and appropriate opioid use.Methods: Six databases were searched (MEDLINE, EMBASE, Scopus, PsycINFO, CENTRAL and Cochrane Methodology Register) from inception to March 2023. The protocol was registered in PROSPERO (CRD42023401895).Results: Twenty-nine studies identified five key areas of pharmacist interventions in opioid management-naloxone programs and opioid de-escalation, patient and primary healthcare providers' education and motivational interview, prescription monitoring and opioid risk screening, clinical pharmacy interventions (pharmacotherapy, medication review, prescribing, adherence monitoring), and collaborative healthcare approaches to promote optimal opioid use. Outcomes assessment indicated harm reduction, improved safety, increased non-opioid analgesic use, decreased opioid consumption, and enhanced pain management.Conclusion: This review underscores pharmacists' vital role in tackling opioid misuse, overuse and abuse, providing a foundation for evidence-based policies to minimize harm and promote optimal opioid use.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"519-529"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"Trying to explain the unexplainable": why research on contextual factors in musculoskeletal pain is needed. "试图解释无法解释的问题"：为什么需要对肌肉骨骼疼痛的环境因素进行研究？

IF 1.4

Pain management Pub Date : 2024-09-01 Epub Date: 2024-09-27 DOI: 10.1080/17581869.2024.2406224

Giacomo Rossettini, Alvisa Palese, Chad Cook

引用次数: 0

Polmacoxib 2mg in patients with mild to moderate idiopathic osteoarthritis of hip/knee-a randomized, double-anonymous study. 针对轻度至中度特发性髋关节/膝关节骨关节炎患者的 2 毫克波马昔布--一项随机、双匿名研究。

IF 1.4

Pain management Pub Date : 2024-09-01 Epub Date: 2024-11-15 DOI: 10.1080/17581869.2024.2427944

Shubhadeep D Sinha, Tadikonda Bhavani Prasad, Bhaskar Konatham, Sreenivasa Chary Sriramadasu, Arnab Karmakar, Arun Kumar Sharma, Rakesh Verma, Srinivas Reddy Devireddy, Mohan Reddy Bandi, Muralidhar Panapakam

{"title":"Polmacoxib 2mg in patients with mild to moderate idiopathic osteoarthritis of hip/knee-a randomized, double-anonymous study.","authors":"Shubhadeep D Sinha, Tadikonda Bhavani Prasad, Bhaskar Konatham, Sreenivasa Chary Sriramadasu, Arnab Karmakar, Arun Kumar Sharma, Rakesh Verma, Srinivas Reddy Devireddy, Mohan Reddy Bandi, Muralidhar Panapakam","doi":"10.1080/17581869.2024.2427944","DOIUrl":"10.1080/17581869.2024.2427944","url":null,"abstract":"Aim: Polmacoxib, a new COX-2 inhibitor with carbonic anhydrase (CA) inhibitory action, is expected to help minimize the adverse effects associated with other NSAIDs, like GI (gastrointestinal) and CV (cardiovascular) system- related issues. The comparative efficacy and safety of polmacoxib 2 mg (manufactured by Hetero Labs Limited) versus celecoxib 200 mg (manufactured by Hetero Labs Limited) were assessed in this randomized, double-anonymous, clinical study in Indian adult patients diagnosed with idiopathic osteoarthritis (OA) of the.Patients & methodology: 18 years and older patients of either sex, clinically and radiographically diagnosed idiopathic knee or hip OA were randomized to receive either polmacoxib or celecoxib in a 1:1 ratio. All patients were assessed with various pain measuring scales and recorded the scores at the end of weeks 3 and 6.Conclusion: The data for all the pain assessment scores were analyzed, and polmacoxib was found to be a non-inferior therapeutic agent compared to celecoxib in terms of safety and efficacy.(https://ctri.nic.in/CTRI/2022/05/042923).","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"497-506"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of responders and nonresponders with knee osteoarthritis after transcranial direct current stimulation. 经颅直流电刺激后膝关节骨关节炎有反应者与无反应者的比较。

IF 1.4

Pain management Pub Date : 2024-09-01 Epub Date: 2024-11-16 DOI: 10.1080/17581869.2024.2429943

Juyoung Park, Heling Tong, Yixin Kang, Hongyu Miao, Lifeng Lin, Rina S Fox, Ilknur Telkes, Geraldine Martorella, Hyochol Ahn

{"title":"Comparison of responders and nonresponders with knee osteoarthritis after transcranial direct current stimulation.","authors":"Juyoung Park, Heling Tong, Yixin Kang, Hongyu Miao, Lifeng Lin, Rina S Fox, Ilknur Telkes, Geraldine Martorella, Hyochol Ahn","doi":"10.1080/17581869.2024.2429943","DOIUrl":"10.1080/17581869.2024.2429943","url":null,"abstract":"Aim: The study compared responders and nonresponders to transcranial direct current stimulation (tDCS) regarding clinical pain outcomes in knee osteoarthritis (OA) patients.Patients and methods/materials: Sixty participants received home-based active tDCS, and clinical pain outcomes were compared between responders and nonresponders.Results: Latent class growth analyses classified 41 participants as responders and 19 as nonresponders. Responders showed significantly greater decreases in pain intensity from baseline to post intervention than nonresponders (p < .001). Participants with higher BMI (p = .02) and weight (p = .005) were more likely to respond, while no significant sociodemographic differences were found.Conclusions: Identifying characteristics of nonresponsive tDCS subgroups can tailor treatments for each group.Clinical trial registration: www.clinicaltrials.gov identifier is NCT04016272.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"507-518"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidural spread of surgical site infection from spinal cord stimulation trial. 脊髓刺激试验引起的手术部位感染的硬膜外扩散。

IF 1.4

Pain management Pub Date : 2024-06-02 Epub Date: 2024-07-08 DOI: 10.1080/17581869.2024.2373044

Taif Mukhdomi, Bennett Andrassy, Semih Gungor

引用次数: 0